Core Insights - Harrow has launched a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, aimed at providing affordable FDA-approved ophthalmic products as alternatives to off-label compounded formulations [1][2]. Product Offering - PharmaPack kits are designed to enhance access to FDA-approved ophthalmic products for millions of Americans needing infection control and treatment of pain and inflammation related to cataract surgery [2]. - The kits simplify the prescribing process by eliminating insurance-related administrative complexities and reducing regulatory and medical-legal risks associated with off-label compounded products [2]. Market Demand - The PharmaPack program addresses a significant challenge in ophthalmology by providing reliable and affordable FDA-approved therapies, which has been a request from optometrists [4]. - The offering is expected to foster greater confidence among prescribers when considering FDA-approved branded alternatives to compounded products [4]. Availability and Expansion - Initially, PharmaPack kits will be available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans for nationwide expansion in the coming weeks [6].